Taiwan
· Delayed Price · Currency is TWD Gongwin Biopharm Holdings Statistics
Total Valuation
Gongwin Biopharm Holdings has a market cap or net worth of TWD 15.30 billion. The enterprise value is 12.66 billion.
| Market Cap | 15.30B |
| Enterprise Value | 12.66B |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
| Earnings Date | Nov 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Gongwin Biopharm Holdings has 127.51 million shares outstanding. The number of shares has increased by 1.00% in one year.
| Shares Outstanding | 127.51M |
| Shares Change (YoY) | +1.00% |
| Shares Change (QoQ) | +1.81% |
| Owned by Insiders (%) | 16.46% |
| Owned by Institutions (%) | 0.05% |
| Float | 103.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 430.99 |
| PB Ratio | 4.62 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -115.01 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -44.85 |
Financial Position
The company has a current ratio of 10.28, with a Debt / Equity ratio of 7.30.
| Current Ratio | 10.28 |
| Quick Ratio | 9.70 |
| Debt / Equity | 7.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.86 |
| Interest Coverage | -37.82 |
Financial Efficiency
Return on equity (ROE) is -4.56% and return on invested capital (ROIC) is -3.41%.
| Return on Equity (ROE) | -4.56% |
| Return on Assets (ROA) | -3.24% |
| Return on Capital (ROIC) | -3.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.71 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.43% in the last 52 weeks. The beta is 0.79, so Gongwin Biopharm Holdings's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -34.43% |
| 50-Day Moving Average | 125.16 |
| 200-Day Moving Average | 167.46 |
| Relative Strength Index (RSI) | 44.07 |
| Average Volume (20 Days) | 479,488 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gongwin Biopharm Holdings had revenue of TWD 31.71 million and -110.05 million in losses. Loss per share was -0.97.
| Revenue | 31.71M |
| Gross Profit | 23.00M |
| Operating Income | -137.87M |
| Pretax Income | -106.20M |
| Net Income | -110.05M |
| EBITDA | -130.03M |
| EBIT | -137.87M |
| Loss Per Share | -0.97 |
Balance Sheet
The company has 2.88 billion in cash and 241.60 million in debt, giving a net cash position of 2.64 billion or 20.68 per share.
| Cash & Cash Equivalents | 2.88B |
| Total Debt | 241.60M |
| Net Cash | 2.64B |
| Net Cash Per Share | 20.68 |
| Equity (Book Value) | 3.31B |
| Book Value Per Share | 26.00 |
| Working Capital | 2.77B |
Cash Flow
In the last 12 months, operating cash flow was -82.36 million and capital expenditures -199.84 million, giving a free cash flow of -282.20 million.
| Operating Cash Flow | -82.36M |
| Capital Expenditures | -199.84M |
| Free Cash Flow | -282.20M |
| FCF Per Share | -2.21 |
Margins
| Gross Margin | 72.55% |
| Operating Margin | -434.81% |
| Pretax Margin | -334.94% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -890.01% |
Dividends & Yields
Gongwin Biopharm Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.00% |
| Shareholder Yield | -1.00% |
| Earnings Yield | -0.81% |
| FCF Yield | -1.84% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |